A228760 Stock Overview
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genomictree Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,550.00 |
| 52 Week High | ₩30,950.00 |
| 52 Week Low | ₩11,600.00 |
| Beta | 0.038 |
| 1 Month Change | 3.29% |
| 3 Month Change | 27.85% |
| 1 Year Change | 92.09% |
| 3 Year Change | 64.11% |
| 5 Year Change | -28.31% |
| Change since IPO | 423.33% |
Recent News & Updates
Shareholder Returns
| A228760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 7.3% | 4.1% | 0.5% |
| 1Y | 92.1% | 6.6% | 4.7% |
Return vs Industry: A228760 exceeded the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A228760 exceeded the KR Market which returned 4.7% over the past year.
Price Volatility
| A228760 volatility | |
|---|---|
| A228760 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A228760's share price has been volatile over the past 3 months.
Volatility Over Time: A228760's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 80 | Sung-Whan An | www.genomictree.com |
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers.
Genomictree Inc. Fundamentals Summary
| A228760 fundamental statistics | |
|---|---|
| Market cap | ₩556.53b |
| Earnings (TTM) | -₩8.76b |
| Revenue (TTM) | ₩3.42b |
162.8x
P/S Ratio-63.6x
P/E RatioIs A228760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A228760 income statement (TTM) | |
|---|---|
| Revenue | ₩3.42b |
| Cost of Revenue | ₩3.72b |
| Gross Profit | -₩301.62m |
| Other Expenses | ₩8.45b |
| Earnings | -₩8.76b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -370.52 |
| Gross Margin | -8.82% |
| Net Profit Margin | -256.17% |
| Debt/Equity Ratio | 1.4% |
How did A228760 perform over the long term?
See historical performance and comparison